Altre lingue Samsung Biologics Co.,Ltd.

Azioni

A207940

KR7207940008

Prezzo di chiusura Korea S.E. Altri mercati azionari 00:00:00 25/04/2024			Variaz. 5gg	Var. 1 gen.
780.000 ^KRW	-1,27%		-1,27%	+2,63%

25/04	Samsung Bioepis ha ottenuto l'approvazione per la commercializzazione di un trattamento autoimmune in Europa	MT
25/04	Samsung Biologics registra un aumento dell'utile e delle vendite nel 1° trimestre	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Samsung Biologics Reports First Quarter 2024 Financial Results	25/04
Samsung Bioepis Granted Approval to Market Autoimmune Treatment in Europe	25/04
Samsung Biologics Posts Higher Q1 Profit, Sales	25/04
Samsung Biologics Boosts Contract Size with MSD Switzerland	08/04
Samsung Life Science Fund Invests in BrickBio	20/03
Samsung Life Science Fund Invests in Biologics Developer	20/03
CEO IR Newsletter : 2024 AGM Wrap Up	15/03
Samsung Biologics : hosts 13th Annual General Meeting of Shareholders	15/03
Samsung Group Initiates Open Hiring Drive for New Talent Acquisition	12/03
South Korean Shares Close Higher After US Fed Chief Hints at Rate Cuts; Samsung Biologics Adds 1%	07/03
Samsung Biologics Strikes $353 Million Deal with Belgium's UCB	07/03
Samsung Biologics signs MOU with Seoul National University to foster bio experts	01/03
South Korean Shares Dip on Tech, Pharma Losses; Celltrion Sheds 5% on Lackluster Q4 Earnings	29/02
Samsung Biologics Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Samsung Biologics awarded Leadership status by CDP for climate action efforts	14/02
Samsung Biologics Collaborates with LegoChem Biosciences on ADC Development and Manufacturing	09/02
Samsung Biologics partners with LegoChem Biosciences for ADC development and manufacturing	08/02
Samsung chair found not guilty of charges connected to 2015 merger	05/02
Samsung chief Lee Jae-yong is acquitted of financial crimes related to 2015 merger	05/02
Samsung chief acquitted in controversial 2015 merger case	05/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Samsung Biologics Co.,Ltd.

Azioni

A207940

KR7207940008

Altre lingue

Filtri